Hematological Malignancies

Therapeutic issues

• Risk of CNS recurrence associated with skeletal involvement is a matter of debate, with rates of 4% and 0.6% respectively for DLCL patients with and without skeletal involvement

• In the IELSG-14 study, CNS involvement occurred in 2.5% of patients with primary bone DLCL

• Available evidence suggests that CNS prophylaxis is superfluous in primary bone DLCL